|
||||||
|
 | Fusion Gene Summary |
| Fusion Gene ORF analysis |
| Fusion Genomic Features |
| Fusion Protein Features |
| Fusion Gene Sequence |
| Fusion Gene PPI analysis |
| Related Drugs |
| Related Diseases |
Fusion gene:LATS2-CRYL1 (FusionGDB2 ID:44208) |
Fusion Gene Summary for LATS2-CRYL1 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: LATS2-CRYL1 | Fusion gene ID: 44208 | Hgene | Tgene | Gene symbol | LATS2 | CRYL1 | Gene ID | 26524 | 51084 |
| Gene name | large tumor suppressor kinase 2 | crystallin lambda 1 | |
| Synonyms | KPM | GDH|HEL30|gul3DH|lambda-CRY | |
| Cytomap | 13q12.11 | 13q12.11 | |
| Type of gene | protein-coding | protein-coding | |
| Description | serine/threonine-protein kinase LATS2LATS (large tumor suppressor, Drosophila) homolog 2LATS, large tumor suppressor, homolog 2kinase phosphorylated during mitosis proteinlarge tumor suppressor homolog 2serine/threonine kinase KPMserine/threonine-pr | lambda-crystallin homologL-gulonate 3-dehydrogenasecrystallin, lamda 1epididymis luminal protein 30testicular tissue protein Li 44 | |
| Modification date | 20200313 | 20200313 | |
| UniProtAcc | Q9NRM7 | Q9Y2S2 | |
| Ensembl transtripts involved in fusion gene | ENST00000382592, ENST00000542899, ENST00000472754, | ENST00000480748, ENST00000298248, ENST00000382812, | |
| Fusion gene scores | * DoF score | 4 X 6 X 3=72 | 15 X 9 X 10=1350 |
| # samples | 5 | 17 | |
| ** MAII score | log2(5/72*10)=-0.526068811667588 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(17/1350*10)=-2.98935275580049 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context | PubMed: LATS2 [Title/Abstract] AND CRYL1 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint | LATS2(21619824)-CRYL1(21063635), # samples:1 | ||
| Anticipated loss of major functional domain due to fusion event. | LATS2-CRYL1 seems lost the major protein functional domain in Hgene partner, which is a CGC due to the frame-shifted ORF. LATS2-CRYL1 seems lost the major protein functional domain in Hgene partner, which is a IUPHAR drug target due to the frame-shifted ORF. LATS2-CRYL1 seems lost the major protein functional domain in Hgene partner, which is a kinase due to the frame-shifted ORF. LATS2-CRYL1 seems lost the major protein functional domain in Hgene partner, which is a tumor suppressor due to the frame-shifted ORF. LATS2-CRYL1 seems lost the major protein functional domain in Tgene partner, which is a essential gene due to the frame-shifted ORF. | ||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | LATS2 | GO:0000082 | G1/S transition of mitotic cell cycle | 12853976 |
| Hgene | LATS2 | GO:0006468 | protein phosphorylation | 10871863 |
| Hgene | LATS2 | GO:0009755 | hormone-mediated signaling pathway | 15131260 |
| Hgene | LATS2 | GO:0035329 | hippo signaling | 20412773 |
| Hgene | LATS2 | GO:0035556 | intracellular signal transduction | 10871863 |
| Hgene | LATS2 | GO:0045736 | negative regulation of cyclin-dependent protein serine/threonine kinase activity | 12853976 |
| Fusion gene breakpoints across LATS2 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
| Fusion gene breakpoints across CRYL1 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
| Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChimerDB4 | STAD | TCGA-D7-8570-01A | LATS2 | chr13 | 21619824 | - | CRYL1 | chr13 | 21063635 | - |
Top |
Fusion Gene ORF analysis for LATS2-CRYL1 |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| 5CDS-intron | ENST00000382592 | ENST00000480748 | LATS2 | chr13 | 21619824 | - | CRYL1 | chr13 | 21063635 | - |
| 5CDS-intron | ENST00000542899 | ENST00000480748 | LATS2 | chr13 | 21619824 | - | CRYL1 | chr13 | 21063635 | - |
| Frame-shift | ENST00000542899 | ENST00000298248 | LATS2 | chr13 | 21619824 | - | CRYL1 | chr13 | 21063635 | - |
| Frame-shift | ENST00000542899 | ENST00000382812 | LATS2 | chr13 | 21619824 | - | CRYL1 | chr13 | 21063635 | - |
| In-frame | ENST00000382592 | ENST00000298248 | LATS2 | chr13 | 21619824 | - | CRYL1 | chr13 | 21063635 | - |
| In-frame | ENST00000382592 | ENST00000382812 | LATS2 | chr13 | 21619824 | - | CRYL1 | chr13 | 21063635 | - |
| intron-3CDS | ENST00000472754 | ENST00000298248 | LATS2 | chr13 | 21619824 | - | CRYL1 | chr13 | 21063635 | - |
| intron-3CDS | ENST00000472754 | ENST00000382812 | LATS2 | chr13 | 21619824 | - | CRYL1 | chr13 | 21063635 | - |
| intron-intron | ENST00000472754 | ENST00000480748 | LATS2 | chr13 | 21619824 | - | CRYL1 | chr13 | 21063635 | - |
| ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| ENST00000382592 | LATS2 | chr13 | 21619824 | - | ENST00000298248 | CRYL1 | chr13 | 21063635 | - | 2021 | 748 | 755 | 1558 | 267 |
| ENST00000382592 | LATS2 | chr13 | 21619824 | - | ENST00000382812 | CRYL1 | chr13 | 21063635 | - | 2017 | 748 | 755 | 1558 | 267 |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
| ENST00000382592 | ENST00000298248 | LATS2 | chr13 | 21619824 | - | CRYL1 | chr13 | 21063635 | - | 0.006683477 | 0.99331653 |
| ENST00000382592 | ENST00000382812 | LATS2 | chr13 | 21619824 | - | CRYL1 | chr13 | 21063635 | - | 0.00668521 | 0.9933148 |
Top |
Fusion Genomic Features for LATS2-CRYL1 |
| FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
| Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
 |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
Top |
Fusion Protein Features for LATS2-CRYL1 |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr13:21619824/chr13:21063635) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| LATS2 | CRYL1 |
| FUNCTION: Negative regulator of YAP1 in the Hippo signaling pathway that plays a pivotal role in organ size control and tumor suppression by restricting proliferation and promoting apoptosis. The core of this pathway is composed of a kinase cascade wherein STK3/MST2 and STK4/MST1, in complex with its regulatory protein SAV1, phosphorylates and activates LATS1/2 in complex with its regulatory protein MOB1, which in turn phosphorylates and inactivates YAP1 oncoprotein and WWTR1/TAZ. Phosphorylation of YAP1 by LATS2 inhibits its translocation into the nucleus to regulate cellular genes important for cell proliferation, cell death, and cell migration. Acts as a tumor suppressor which plays a critical role in centrosome duplication, maintenance of mitotic fidelity and genomic stability. Negatively regulates G1/S transition by down-regulating cyclin E/CDK2 kinase activity. Negative regulator of the androgen receptor. Phosphorylates SNAI1 in the nucleus leading to its nuclear retention and stabilization, which enhances its epithelial-mesenchymal transition and tumor cell invasion/migration activities. This tumor-promoting activity is independent of its effects upon YAP1 or WWTR1/TAZ. {ECO:0000269|PubMed:10871863, ECO:0000269|PubMed:12853976, ECO:0000269|PubMed:15131260, ECO:0000269|PubMed:18158288, ECO:0000269|PubMed:21952048}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Hgene | LATS2 | chr13:21619824 | chr13:21063635 | ENST00000382592 | - | 2 | 8 | 668_973 | 114 | 1089.0 | Domain | Protein kinase |
| Hgene | LATS2 | chr13:21619824 | chr13:21063635 | ENST00000382592 | - | 2 | 8 | 974_1052 | 114 | 1089.0 | Domain | AGC-kinase C-terminal |
| Hgene | LATS2 | chr13:21619824 | chr13:21063635 | ENST00000382592 | - | 2 | 8 | 98_139 | 114 | 1089.0 | Domain | UBA |
| Hgene | LATS2 | chr13:21619824 | chr13:21063635 | ENST00000542899 | - | 2 | 8 | 668_973 | 114 | 1089.0 | Domain | Protein kinase |
| Hgene | LATS2 | chr13:21619824 | chr13:21063635 | ENST00000542899 | - | 2 | 8 | 974_1052 | 114 | 1089.0 | Domain | AGC-kinase C-terminal |
| Hgene | LATS2 | chr13:21619824 | chr13:21063635 | ENST00000542899 | - | 2 | 8 | 98_139 | 114 | 1089.0 | Domain | UBA |
| Hgene | LATS2 | chr13:21619824 | chr13:21063635 | ENST00000382592 | - | 2 | 8 | 515_518 | 114 | 1089.0 | Motif | Note=PPxY motif |
| Hgene | LATS2 | chr13:21619824 | chr13:21063635 | ENST00000542899 | - | 2 | 8 | 515_518 | 114 | 1089.0 | Motif | Note=PPxY motif |
| Hgene | LATS2 | chr13:21619824 | chr13:21063635 | ENST00000382592 | - | 2 | 8 | 674_782 | 114 | 1089.0 | Nucleotide binding | ATP |
| Hgene | LATS2 | chr13:21619824 | chr13:21063635 | ENST00000542899 | - | 2 | 8 | 674_782 | 114 | 1089.0 | Nucleotide binding | ATP |
| Tgene | CRYL1 | chr13:21619824 | chr13:21063635 | ENST00000298248 | 1 | 8 | 16_17 | 49 | 320.0 | Nucleotide binding | NAD | |
| Tgene | CRYL1 | chr13:21619824 | chr13:21063635 | ENST00000382812 | 2 | 9 | 16_17 | 27 | 298.0 | Nucleotide binding | NAD |
Top |
Fusion Gene Sequence for LATS2-CRYL1 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >44208_44208_1_LATS2-CRYL1_LATS2_chr13_21619824_ENST00000382592_CRYL1_chr13_21063635_ENST00000298248_length(transcript)=2021nt_BP=748nt TTGGGTCTGCGCTTTGGAACCGCGGCGTGAGCGCCCCGGGAAGATGGAGCAGTCGCCGTCCACGCCACCGCCGCCGCCCGGGGCTCCCCC GTCCCTGCGGGGCCAGCAGCAGCTCCAGCCACCAGTGCCCGGTCTCCCGGCGCGAGAGGCCCGGGAGCCGCCGGCCAGGACGCCCCCGAG GGTGTAGACCGCGCCCCTGGAGAGAGTGATAATCTTCAAAATGAAGACTTTGGAAAATTTTAGGTTCTCTATAGGAACTACAAAAATGGA AGGAAAGAACATTTTCAAAAGGAAATTATTTTGAAAGTATGTTTACAACAAACTGATACTATTGACAGTTTTTTTTTTTAAATAATAAAA CACTTTAAGAAGATTGTATTTATGGTAAAAGGAAACTGGACTAACAATGAGGCCAAAGACTTTTCCTGCCACGACTTATTCTGGAAATAG CCGGCAGCGACTGCAAGAGATTCGTGAGGGGTTAAAACAGCCATCCAAGTCTTCGGTTCAGGGGCTACCCGCAGGACCAAACAGTGACAC TTCCCTGGATGCCAAAGTCCTGGGGAGCAAAGATGCCACCAGGCAGCAGCAGCAGATGAGAGCCACCCCAAAGTTCGGACCTTATCAGAA AGCCTTGAGGGAAATCAGATATTCCTTGTTGCCTTTTGCTAATGAATCGGGCACCTCTGCAGCTGCAGAAGTGAACCGGCAAATGCTGCA GGAACTGGTGAACGCAGGATGCGACCAGAAAGGAGATGAAGTTGCTGGAGCAGGCAGGTTCTCTGAAAGGCTCCCTGAGTGTGGAAGAGC AGCTGTCACTCATCAGTGGTTGTCCCAATATCCAAGAAGCAGTAGAGGGTGCCATGCACATTCAGGAATGTGTTCCAGAAGATCTAGAAC TGAAGAAGAAGATTTTTGCTCAGTTAGATTCCATCATTGATGATCGAGTGATCTTAAGCAGTTCCACTTCTTGTCTCATGCCTTCCAAGT TGTTTGCTGGCTTGGTCCATGTGAAGCAATGCATCGTGGCTCATCCTGTGAATCCGCCATACTACATCCCGCTGGTTGAGCTGGTCCCCC ACCCGGAGACGGCCCCTACGACAGTGGACAGAACCCACGCCCTGATGAAGAAGATTGGACAGTGCCCCATGCGAGTCCAGAAGGAGGTGG CCGGCTTCGTTCTGAACCGCCTGCAATATGCAATCATCAGCGAGGCCTGGCGGCTAGTGGAGGAAGGAATCGTGTCTCCTAGTGACCTGG ACCTTGTCATGTCAGAAGGGTTGGGCATGCGGTATGCATTCATTGGACCCCTGGAAACCATGCATCTCAATGCAGAAGGTATGTTAAGCT ACTGCGACAGATACAGCGAAGGCATAAAACATGTCCTACAGACTTTTGGACCCATTCCAGAGTTTTCCAGGGCCACTGCTGAGAAGGTTA ACCAGGACATGTGCATGAAGGTCCCTGATGACCCGGAGCACTTAGCTGCCAGGAGGCAGTGGAGGGACGAGTGCCTCATGAGACTCGCCA AGTTGAAGAGTCAAGTGCAGCCCCAGTGAATTTCTTGTAATGCAGCTTCCACTCCTCTCATTGGAGGCCCTATTTGGGAACACTGCAAGC CCTTAATCAGCCCTCTGTGACATAGGTAGCAGCCCACGGAGATCCTAAGCTGGCTGTCTTGTGTGCAGCCTGAGTGGGGTGGTGCAGGCC GGTAGTCTGCCCGTCACTTTGGATCATAGCCCTGGGCCTGGCGGCACAGCAGCACTTGCGTTCTCGGGGCTGTCGATTTCCTGCCACCTG GGCAGATAACCTGGAGATTTTCACCTTTTCTTTTCAGCTTGATTGCATTTGACTATATTTTACAGCCAGTGATTGTAGTTTCATGTTAAT ATGTGGCAAAATATTTTTGTAATTATTTTCTAATCCCTTTCTGAGTACTCTGGGGCCCTGCATTTATGAGGCACCTACCTTCATTTTGCT >44208_44208_1_LATS2-CRYL1_LATS2_chr13_21619824_ENST00000382592_CRYL1_chr13_21063635_ENST00000298248_length(amino acids)=267AA_BP=0 MKLLEQAGSLKGSLSVEEQLSLISGCPNIQEAVEGAMHIQECVPEDLELKKKIFAQLDSIIDDRVILSSSTSCLMPSKLFAGLVHVKQCI VAHPVNPPYYIPLVELVPHPETAPTTVDRTHALMKKIGQCPMRVQKEVAGFVLNRLQYAIISEAWRLVEEGIVSPSDLDLVMSEGLGMRY -------------------------------------------------------------- >44208_44208_2_LATS2-CRYL1_LATS2_chr13_21619824_ENST00000382592_CRYL1_chr13_21063635_ENST00000382812_length(transcript)=2017nt_BP=748nt TTGGGTCTGCGCTTTGGAACCGCGGCGTGAGCGCCCCGGGAAGATGGAGCAGTCGCCGTCCACGCCACCGCCGCCGCCCGGGGCTCCCCC GTCCCTGCGGGGCCAGCAGCAGCTCCAGCCACCAGTGCCCGGTCTCCCGGCGCGAGAGGCCCGGGAGCCGCCGGCCAGGACGCCCCCGAG GGTGTAGACCGCGCCCCTGGAGAGAGTGATAATCTTCAAAATGAAGACTTTGGAAAATTTTAGGTTCTCTATAGGAACTACAAAAATGGA AGGAAAGAACATTTTCAAAAGGAAATTATTTTGAAAGTATGTTTACAACAAACTGATACTATTGACAGTTTTTTTTTTTAAATAATAAAA CACTTTAAGAAGATTGTATTTATGGTAAAAGGAAACTGGACTAACAATGAGGCCAAAGACTTTTCCTGCCACGACTTATTCTGGAAATAG CCGGCAGCGACTGCAAGAGATTCGTGAGGGGTTAAAACAGCCATCCAAGTCTTCGGTTCAGGGGCTACCCGCAGGACCAAACAGTGACAC TTCCCTGGATGCCAAAGTCCTGGGGAGCAAAGATGCCACCAGGCAGCAGCAGCAGATGAGAGCCACCCCAAAGTTCGGACCTTATCAGAA AGCCTTGAGGGAAATCAGATATTCCTTGTTGCCTTTTGCTAATGAATCGGGCACCTCTGCAGCTGCAGAAGTGAACCGGCAAATGCTGCA GGAACTGGTGAACGCAGGATGCGACCAGAAAGGAGATGAAGTTGCTGGAGCAGGCAGGTTCTCTGAAAGGCTCCCTGAGTGTGGAAGAGC AGCTGTCACTCATCAGTGGTTGTCCCAATATCCAAGAAGCAGTAGAGGGTGCCATGCACATTCAGGAATGTGTTCCAGAAGATCTAGAAC TGAAGAAGAAGATTTTTGCTCAGTTAGATTCCATCATTGATGATCGAGTGATCTTAAGCAGTTCCACTTCTTGTCTCATGCCTTCCAAGT TGTTTGCTGGCTTGGTCCATGTGAAGCAATGCATCGTGGCTCATCCTGTGAATCCGCCATACTACATCCCGCTGGTTGAGCTGGTCCCCC ACCCGGAGACGGCCCCTACGACAGTGGACAGAACCCACGCCCTGATGAAGAAGATTGGACAGTGCCCCATGCGAGTCCAGAAGGAGGTGG CCGGCTTCGTTCTGAACCGCCTGCAATATGCAATCATCAGCGAGGCCTGGCGGCTAGTGGAGGAAGGAATCGTGTCTCCTAGTGACCTGG ACCTTGTCATGTCAGAAGGGTTGGGCATGCGGTATGCATTCATTGGACCCCTGGAAACCATGCATCTCAATGCAGAAGGTATGTTAAGCT ACTGCGACAGATACAGCGAAGGCATAAAACATGTCCTACAGACTTTTGGACCCATTCCAGAGTTTTCCAGGGCCACTGCTGAGAAGGTTA ACCAGGACATGTGCATGAAGGTCCCTGATGACCCGGAGCACTTAGCTGCCAGGAGGCAGTGGAGGGACGAGTGCCTCATGAGACTCGCCA AGTTGAAGAGTCAAGTGCAGCCCCAGTGAATTTCTTGTAATGCAGCTTCCACTCCTCTCATTGGAGGCCCTATTTGGGAACACTGCAAGC CCTTAATCAGCCCTCTGTGACATAGGTAGCAGCCCACGGAGATCCTAAGCTGGCTGTCTTGTGTGCAGCCTGAGTGGGGTGGTGCAGGCC GGTAGTCTGCCCGTCACTTTGGATCATAGCCCTGGGCCTGGCGGCACAGCAGCACTTGCGTTCTCGGGGCTGTCGATTTCCTGCCACCTG GGCAGATAACCTGGAGATTTTCACCTTTTCTTTTCAGCTTGATTGCATTTGACTATATTTTACAGCCAGTGATTGTAGTTTCATGTTAAT ATGTGGCAAAATATTTTTGTAATTATTTTCTAATCCCTTTCTGAGTACTCTGGGGCCCTGCATTTATGAGGCACCTACCTTCATTTTGCT >44208_44208_2_LATS2-CRYL1_LATS2_chr13_21619824_ENST00000382592_CRYL1_chr13_21063635_ENST00000382812_length(amino acids)=267AA_BP=0 MKLLEQAGSLKGSLSVEEQLSLISGCPNIQEAVEGAMHIQECVPEDLELKKKIFAQLDSIIDDRVILSSSTSCLMPSKLFAGLVHVKQCI VAHPVNPPYYIPLVELVPHPETAPTTVDRTHALMKKIGQCPMRVQKEVAGFVLNRLQYAIISEAWRLVEEGIVSPSDLDLVMSEGLGMRY -------------------------------------------------------------- |
Top |
Fusion Gene PPI Analysis for LATS2-CRYL1 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for LATS2-CRYL1 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
Related Diseases for LATS2-CRYL1 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies